Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation
- Author(s)
- Bekadja, MA; Niederwiser, D; Kharfan-Dabaja, MA; El Fakih, R; Garderet, L; Yakoub-Agha, I; Greinix, H; Weisdorf, DJ; Galeano, S; Ahmed, SO; Chabanon, C; Hashmi, SK; Ruggeri, A; Gergis, U; Bazarbachi, A; Hamad, N; Albeihany, A; Pasquini, M; Hanbali, A; Szer, J; Kodera, Y; Kumar, A; Elhassan, T; McLornan, D; Worel, N; Greco, R; Mohty, M; Atsuta, Y; Koh, M; Sureda, A; Rondelli, D; Aljurf, M; Rasheed, W;
- Journal Title
- Bone Marrow Transplantation
- Publication Type
- Online publication before print
- Abstract
- Autologous peripheral blood stem cell (PBSC) transplantation is a standard treatment of multiple myeloma (MM), Hodgkin lymphoma and various subtypes of non-Hodgkin lymphoma. Cryopreservation of hematopoietic stem cells is standard practice that allows time for delivery of conditioning regimen prior to cell infusion. The aim of this Worldwide Network for Blood & Marrow Transplantation (WBMT) work was to assess existing evidence on non-cryopreserved autologous transplants through a systematic review/meta-analysis, to study feasibility and safety of this approach. We searched PubMed, Web of Science and SCOPUS for studies that utilized non-cryopreserved autologous PBSC transplantation. Identified literature was reviewed for information on mobilization, apheresis, preservation and viability, conditioning regimen, engraftment, response, and survival. Results highlight collective experience from 19 transplant centers (1686 patients), that performed autologous transplants using non-cryopreserved PBSCs. The mean of infused CD34+ was 5.6 × 10(6)/kg. Stem cell viability at transplantation was >90% in MM and >75% in lymphomas, after a storage time of 24-144 h at +4 °C. Mean time-to-neutrophil engraftment was 12 days and 15.3 days for platelets. Pooled proportion estimates of day 100 transplant-related mortality and graft failure were 1% and 0%, respectively. Non-cryopreservation of apheresed autologous PBSCs appears feasible and safe.
- Department(s)
- Clinical Haematology
- Publisher's Version
- https://doi.org/10.1038/s41409-024-02431-y
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-10-22 06:20:35
Last Modified: 2024-10-22 06:25:51